| |
|
|
| |
|
|
| |
Sense Beyond is a startup developing a non invasive (NI), wrist-watch-like, real time, continuous blood glucose monitoring (CBG) device, based on a technique different than those tried so far. NI CGB is widely regarded as the most sought after medical challenge following cancer cure. Numerous companies have pursued this life-altering technology, but all have fallen short of achieving the requisite accuracy and consistency. Our technology is unique; signals from other materials than glucose that are "noise" for existing methods, actually improve our accuracy, i.e. auto- calibration and environmental immunity are built-in. The more "noise" – the better the accuracy; we expect accuracies at least as good as the currently used blood-based methods.
The founders of Sense Beyond are an accomplished team of experts covering all aspects necessary to successfully bringing this technology to the market: RF & DSP knowhow, regulatory expertise, business development and long-term financial commitment.
| |
| |
|
|
| |
Status: Initial Proof of Concept done in a lab set-up using measurements obtained from diverse blood constituents and human volunteers. The results confirm theory and exhibit the expected sensitivity at this time. We are currently perfecting our set-up and algorithms to solidify our results, in preparation for the next phase defined here.
Plans: pre-productization phase, possibly with a Singaporean partner.
starting Feb-2012: (i) repeat the mapping of required materials in our set-up according to regulatory requirements (we suggest to do this both in Israel and Singapore); (ii) building a portable device (not the final miniaturized one, that is planned for the following stage) by translating the lab set-up into our own H/W (planned in Israel); (iii) conducting clinical trials at hospitals using the portable device for proving the requisite accuracy (we propose this part to be led and mostly performed by the Singaporean partner).
| |
| |
The preferred Partner would be an established Medical Devices company that will participate in the project in return for distribution rights in Asia Pacific.
During this part of the project, the Singaporean partner role will be to conduct the mapping of the required materials by using a duplicate of our set- up from Israel and then, upon completion of the portable prototypes by the Israeli partner, to conduct the clinical trials in hospitals. As mentioned above, our estimate for this part is two years. The role of the Singaporean partner in the following phase (outside the scope of this part of the project - productization, regulatory path and launch) will be discussed in due course. Both parties are expected to get a local Government grant between 30% to 50% of the respective budget.
| |
|